The company is dedicated to creating innovative therapeutic solutions for pressing medical requirements within neurotology and central nervous system disorders. Based in Zug, Switzerland, the firm operates with a modest team of 11 full-time employees. A significant part of its developmental pipeline focuses on intranasal betahistine, specifically AM-125 for addressing vertigo and AM-201 for mitigating antipsychotic-induced weight gain and somnolence. Both betahistine programs are currently in their initial Phase 1 clinical trial stage. Beyond these, the company's product portfolio includes several other promising candidates. Among them are AM-111, a brimapitide-based compound targeting acute inner ear hearing loss, and Keyzilen (AM-101), an eskatemine-based treatment for acute inner ear tinnitus; both are advanced to Phase 3 clinical trials. Additionally, AM-102, another potential treatment for tinnitus, is undergoing preclinical evaluation aimed at identifying the optimal lead compound. The company maintains its operational presence through subsidiary entities located in Switzerland, Ireland, and the United States.